PMC:7195088 / 64233-64387 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"683","span":{"begin":75,"end":83},"obj":"Species"},{"id":"950","span":{"begin":89,"end":97},"obj":"Disease"}],"attributes":[{"id":"A683","pred":"tao:has_database_id","subj":"683","obj":"Tax:9606"},{"id":"A950","pred":"tao:has_database_id","subj":"950","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T371","span":{"begin":89,"end":97},"obj":"Disease"}],"attributes":[{"id":"A371","pred":"mondo_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T85377","span":{"begin":60,"end":71},"obj":"Chemical"}],"attributes":[{"id":"A3123","pred":"chebi_id","subj":"T85377","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT."}

{"project":"LitCovid-sentences","denotations":[{"id":"T461","span":{"begin":0,"end":154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Owing to the lack of high-level evidence, administration of tocilizumab in patients with COVID-19 should preferentially occur within the framework of RCT."}